Literature DB >> 11041333

Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction.

M Studahl1, L Rosengren, G Günther, L Hagberg.   

Abstract

We determined the extent of neuronal and glial cell destruction in 13 patients with herpes simplex type 1 (HSV-1) encephalitis, 15 patients with tick-borne encephalitis (TBE), and 20 noninfectious controls by analyzing the cerebrospinal fluid (CSF) concentrations of neurofilament protein (a marker of neurons, mainly axons), neuron-specific enolase (a marker of neurons, mainly somas), glial fibrillary acidic protein, and S-100 protein (markers of astrocytes). In addition, in patients with HSV-1 encephalitis CSF samples were collected serially before 7, 8-14, and 18-49 days and 3-10 months after the onset of neurological symptoms. In the acute stage of HSV-1 encephalitis we found markedly higher CSF levels of the cell damage markers than in patients with TBE. The concentration of cell damage markers in HSV-1 encephalitis decreased within 45 days after acute infection, except for neurofilament protein. The CSF concentrations of neurofilament protein increased during the second week, remained extremely high throughout the next month, and decrease thereafter. The changes in these markers of neuronal and glial destruction demonstrate the neuronal and astroglial cell damage during the first month after HSV-1 encephalitis. In contrast, most patients with TBE had signs only of slight astrogliosis, except for two patients with paresis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11041333     DOI: 10.1007/s004150070134

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

1.  A human peripheral blood monocyte-derived subset acts as pluripotent stem cells.

Authors:  Yong Zhao; David Glesne; Eliezer Huberman
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-26       Impact factor: 11.205

2.  In-hospital herpes simplex encephalitis after open heart surgery: an emerging pathology or an under-recognised condition?

Authors:  Mohamed Saleh
Journal:  BMJ Case Rep       Date:  2013-07-10

3.  Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis.

Authors:  M Axelsson; C Malmeström; S Nilsson; S Haghighi; L Rosengren; J Lycke
Journal:  J Neurol       Date:  2011-01-01       Impact factor: 4.849

Review 4.  Immunomodulatory Strategies in Herpes Simplex Virus Encephalitis.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Clin Microbiol Rev       Date:  2020-02-12       Impact factor: 26.132

5.  Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism.

Authors:  Niklas Mattsson; Daniel Bremell; Rolf Anckarsäter; Kaj Blennow; Henrik Anckarsäter; Henrik Zetterberg; Lars Hagberg
Journal:  BMC Neurol       Date:  2010-06-22       Impact factor: 2.474

6.  Prognostic value of intrathecal antibody production and DNA viral load in cerebrospinal fluid of patients with herpes simplex encephalitis.

Authors:  Anders Hjalmarsson; Fredrik Granath; Marianne Forsgren; Maria Brytting; Paul Blomqvist; Birgit Sköldenberg
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

7.  Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections.

Authors:  Anna Grahn; Lars Hagberg; Staffan Nilsson; Kaj Blennow; Henrik Zetterberg; Marie Studahl
Journal:  J Neurol       Date:  2013-03-08       Impact factor: 4.849

8.  Host strain-dependent difference in susceptibility in a rat model of herpes simplex type 1 encephalitis.

Authors:  Biborka Bereczky-Veress; Olle Lidman; Farideh Sabri; Ivan Bednar; Fredrik Granath; Tomas Bergström; Christian Spenger; Alf Grandien; Tomas Olsson; Fredrik Piehl; Margarita Diez; Birgit Sköldenberg
Journal:  J Neurovirol       Date:  2008-04       Impact factor: 2.643

9.  Serum S-100B protein levels in patients with herpes simplex encephalitis and tick-borne encephalitis--a marker of CNS damage during the initial stage of disease.

Authors:  Marie Studahl; Göran Günther; Lars Rosengren
Journal:  J Neurol       Date:  2009-04-09       Impact factor: 4.849

10.  Serum levels of S100B and NSE proteins in Alzheimer's disease patients.

Authors:  Márcia L Chaves; Ana L Camozzato; Eduardo D Ferreira; Isabel Piazenski; Renata Kochhann; Oscar Dall'Igna; Guilherme S Mazzini; Diogo O Souza; Luis V Portela
Journal:  J Neuroinflammation       Date:  2010-01-27       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.